29.39 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||28.68 x 900|
|Ask||32.32 x 900|
|Day's range||28.67 - 30.50|
|52-week range||17.30 - 73.72|
|Beta (5Y monthly)||1.92|
|PE ratio (TTM)||55.24|
|Earnings date||05 May 2020 - 10 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||61.67|
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
Arrowhead dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD for alcohol related and nonalcohol related liver diseases
Arrowhead reports promising interim clinical results of cardiometabolic candidates ARO-APOC3 and ARO-ANG3
Shareholders will be ecstatic, with their stake up 34% over the past week following Arrowhead Pharmaceuticals, Inc.'s...